You just read:

Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone

News provided by

Epizyme, Inc.

Jan 06, 2014, 05:29 EST